Lund, Sweden — 22 October 2024 — Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide)…Original Article
Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly
